TITLE

Review: Framingham risk scores have variable accuracy in predicting CVD events in different patient populations: COMMENTARY

AUTHOR(S)
Havranek, Edward P.
PUB. DATE
May 2007
SOURCE
ACP Journal Club;May/Jun2007, Vol. 146 Issue 3, p80
SOURCE TYPE
Academic Journal
DOC. TYPE
Editorial
ABSTRACT
The author comments on a review of a study on the accuracy of Framingham risk assessments for predicting cardiovascular disease in different groups of patients. He asserted that researchers' predictions based on the Framingham risk scores overestimate in most unselected populations and underestimate in high-risk populations of patients with diabetes. He claimed that the study suggests a good job of determining high-risk patients from those at low risk.
ACCESSION #
25169137

 

Related Articles

  • Diabetes: A Cardiac Condition Manifesting as Hyperglycemia. David Bell // Endocrine Practice;Oct2008, Vol. 14 Issue 7, p924 

    Objective: To investigate the reasons for the increased risk of cardiovascular events and mortality in individuals with type 2 diabetes mellitus.Methods: From January 1990 to March 2008, literature relevant to low-density lipoprotein (LDL) and highdensity lipoprotein (HDL) cholesterol,...

  • ADA, ACC issue consensus statement on cardiometabolic risk. Haigh, Christen; Redberg, Rita F. // Cardiology Today;Jun2008, Vol. 11 Issue 6, p36 

    The article reports on the release of a consensus statement on recommendations for patients with cardiometabolic risk by the American Diabetes Association (ADA) and the American College of Cardiology (ACC), which convened at a consensus development conference from July 18-20, 2007. The...

  • 'Enthusiastic welcome' given to NICE diabetes recommendations.  // Primary Health Care;Sep2004, Vol. 14 Issue 7, p7 

    The article discusses new guidelines for the treatment and care of people with type 1 diabetes. Under the guidelines young people and children should be offered a plan of care that provides ongoing support and outpatient or home-based management on diagnosis, with ongoing care including access...

  • Optimizing treatment reduces CVD risk in patients with diabetes. Haigh, Christen // Cardiology Today;May2008, Vol. 11 Issue 5, p34 

    The article discusses research being done on optimizing cardiovascular disease (CVD) risk reduction in patients with diabetes. It references a study by Cindy Lamendola, presented at the 2008 57th Annual Scientific Session of the American College of Cardiology (ACC). Lamendola argues that when...

  • Women at risk from poor sleep.  // Cardiology Today;May2008, Vol. 11 Issue 5, p1 

    The article focuses on a study which examined the link between sleep quality and cardiovascular risks. The study found that poor quality of sleep is prevalent in women and is linked to the risk of predictive markers of cardiovascular disease and diabetes. It also discovered that poor sleep...

  • Clinical: Warning over age bias in CVD checks. Moberly, Tom // GP: General Practitioner;7/23/2010, p20 

    The article reports that using lifetime risk measures and information on the lifestyle of patients, in risk assessments would help in removing an age-based bias in the patients with cardiovascular disease in Great Britain. According to Keith Fox, professor using cardiovascular risk assessments...

  • Overweight can be used as a tool to guide case-finding for cardiovascular risk assessment. de Boer, Anna W.; de Mutsert, RenĂ©e; den Heijer, Martin; Jukema, Johan W.; Rosendaal, Frits R.; Blom, Jeanet W.; Assendelft, Willem J. J.; NEO study group // Family Practice;Dec2015, Vol. 32 Issue 6, p646 

    Background: In general practice, it is too time-consuming to invite all patients for cardiovascular risk assessment.Objective: To examine how many patients with an indication for treatment with cardiovascular medication can be identified by ad hoc case-finding when all...

  • Is There Clear and Convincing Evidence of Cardiovascular Risk with Rosiglitazone? Kaul, S.; Diamond, G. A. // Clinical Pharmacology & Therapeutics;Jun2011, Vol. 89 Issue 6, p773 

    In this article, the author focuses on the cardiovascular safety of rosiglitazone, a thiazolidinedione drug designed for glycemic control among type 2 diabetics. The author states that meta-analyses conducted by the U.S. Food and Drug Administration (FDA) shows the association of rosiglitazone...

  • Cardiovascular risk factors in a cohort of 30?000 high-risk men and women in the UK: cross-sectional, retrospective and prospective studies of screenees for the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT). Chapman, J N; Kirby, P; Caulfield, M C; Poulter, N R // Journal of Human Hypertension;Aug2001 Supplement, Vol. 15 Issue 8, pS23 

    Focuses on the identification of risk factors for the development of cardiovascular diseases. Requirement of epidemiological studies for the identification of risk factors; Reasons for the need for studies including patients from different ethnic and social backgrounds; Limitations of the...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics